Loading...
Market
What will be the market share of AstraZeneca's FluMist nasal spray vaccine compared to other flu vaccines by end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Market research reports and sales data from AstraZeneca and competitors
Story
FDA Approves AstraZeneca's FluMist Nasal Spray for Self-Administration on Friday
Sep 20, 2024, 04:25 PM
The U.S. Food and Drug Administration (FDA) announced on Friday the approval of AstraZeneca's FluMist nasal spray vaccine for self- or caregiver-administration. This vaccine is designed to prevent influenza caused by influenza virus subtypes A and B in individuals aged 2 through 49 years. The approval is part of the FDA's broader effort to expand consumer access to medicines and reduce costs and barriers to care. AstraZeneca's FluMist is the first influenza vaccine approved for self-administration, marking a significant milestone in public health.
View original story
Similar markets
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
1 to 2 million • 25%
Less than 1 million • 25%
2 to 3 million • 25%
More than 3 million • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Yes • 50%
No • 50%
Very Satisfied • 25%
Satisfied • 25%
Neutral • 25%
Dissatisfied • 25%
Yes • 50%
No • 50%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%